uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. (Onkologisk endokrinologi)
2005 (English)In: Journal of Endocrinological Investigation, ISSN 0391-4097, E-ISSN 1720-8386, Vol. 28, no 11 Suppl International, 137-140 p.Article, review/survey (Other (popular science, discussion, etc.)) Published
Abstract [en]

Somatostatin is a peptide hormone that posses several biological functions of which inhibition of hormone secretion from endocrine cells is one. Neuroendocrine tumors usually express somatostatin receptors (SSTRs), although the subtypes and number of SSTRs expressed in a certain tumor is very variable. The primary goal of somatostatin analog treatment is to decrease hormone production and secretion, resulting in control of hormone induced symptoms, while the ability of somatostatin analogs to retard tumor growth is less well documented. All patients considered for somatostatin analog treatment should undergo SSTR scintigraphy (111In-pentetreotide) to establish SSTR status, since the expression is usually correlated to therapeutic response. By this approach, it is possible to select patients suitable for treatment. Among patients with functioning neuroendocrine tumors expressing SSTR, more than 80% respond with symptomatic relief during somatostatin analog treatment, while treatment of non-functioning tumors still remains somewhat controversial.

Place, publisher, year, edition, pages
2005. Vol. 28, no 11 Suppl International, 137-140 p.
Keyword [en]
Humans, Intestinal Neoplasms/*drug therapy, Neuroendocrine Tumors/*drug therapy, Pancreatic Neoplasms/*drug therapy, Receptors; Somatostatin, Somatostatin/*analogs & derivatives/therapeutic use, Stomach Neoplasms/*drug therapy, Thoracic Neoplasms/*drug therapy
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-21435PubMedID: 16625863OAI: oai:DiVA.org:uu-21435DiVA: diva2:49208
Available from: 2006-12-28 Created: 2006-12-28 Last updated: 2017-12-08Bibliographically approved

Open Access in DiVA

No full text

Other links

PubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16625863&dopt=Citation

Authority records BETA

Janson, Eva Tiensuu

Search in DiVA

By author/editor
Janson, Eva Tiensuu
By organisation
Department of Medical Sciences
In the same journal
Journal of Endocrinological Investigation
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetric score

pubmed
urn-nbn
Total: 384 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf